1114P First-line lenvatinib + pembrolizumab (L + P) vs chemotherapy (CT) for advanced or recurrent endometrial cancer (EC): Additional 1-year follow-up results from ENGOT-en9/LEAP-001.
Saved in:
| Title: | 1114P First-line lenvatinib + pembrolizumab (L + P) vs chemotherapy (CT) for advanced or recurrent endometrial cancer (EC): Additional 1-year follow-up results from ENGOT-en9/LEAP-001. |
|---|---|
| Authors: | Akıllı, H.1 (AUTHOR), Moore, R.G.2 (AUTHOR), Marth, C.3 (AUTHOR), Redondo, T. Diaz4 (AUTHOR), Korach, J.5 (AUTHOR), Stillie, A.6 (AUTHOR), Baurain, J-F.7 (AUTHOR), Mach, P.8 (AUTHOR), Cadoo, K.9 (AUTHOR), Bidzinski, M.10 (AUTHOR), Ariyoshi, K.11 (AUTHOR), Wu, X.12 (AUTHOR), Frentzas, S.13 (AUTHOR), Mattar, A.14 (AUTHOR), Slomovitz, B.M.15 (AUTHOR), Yao, L.16 (AUTHOR), Mckenzie, J.17 (AUTHOR), Meng, R.18 (AUTHOR), Gilbert, L.19 (AUTHOR), Makker, V.20 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS741-S741. 1p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 189419557 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 1114P First-line lenvatinib + pembrolizumab (L + P) vs chemotherapy (CT) for advanced or recurrent endometrial cancer (EC): Additional 1-year follow-up results from ENGOT-en9/LEAP-001. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Akıllı%2C+H%2E%22">Akıllı, H.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Moore%2C+R%2EG%2E%22">Moore, R.G.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Marth%2C+C%2E%22">Marth, C.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Redondo%2C+T%2E+Diaz%22">Redondo, T. Diaz</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Korach%2C+J%2E%22">Korach, J.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Stillie%2C+A%2E%22">Stillie, A.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Baurain%2C+J-F%2E%22">Baurain, J-F.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mach%2C+P%2E%22">Mach, P.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cadoo%2C+K%2E%22">Cadoo, K.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bidzinski%2C+M%2E%22">Bidzinski, M.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ariyoshi%2C+K%2E%22">Ariyoshi, K.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wu%2C+X%2E%22">Wu, X.</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Frentzas%2C+S%2E%22">Frentzas, S.</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mattar%2C+A%2E%22">Mattar, A.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Slomovitz%2C+B%2EM%2E%22">Slomovitz, B.M.</searchLink><relatesTo>15</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Yao%2C+L%2E%22">Yao, L.</searchLink><relatesTo>16</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mckenzie%2C+J%2E%22">Mckenzie, J.</searchLink><relatesTo>17</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Meng%2C+R%2E%22">Meng, R.</searchLink><relatesTo>18</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gilbert%2C+L%2E%22">Gilbert, L.</searchLink><relatesTo>19</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Makker%2C+V%2E%22">Makker, V.</searchLink><relatesTo>20</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2025 Supplement 2, Vol. 36, pS741-S741. 1p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=189419557 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2025.08.1751 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: S741 Titles: – TitleFull: 1114P First-line lenvatinib + pembrolizumab (L + P) vs chemotherapy (CT) for advanced or recurrent endometrial cancer (EC): Additional 1-year follow-up results from ENGOT-en9/LEAP-001. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Akıllı, H. – PersonEntity: Name: NameFull: Moore, R.G. – PersonEntity: Name: NameFull: Marth, C. – PersonEntity: Name: NameFull: Redondo, T. Diaz – PersonEntity: Name: NameFull: Korach, J. – PersonEntity: Name: NameFull: Stillie, A. – PersonEntity: Name: NameFull: Baurain, J-F. – PersonEntity: Name: NameFull: Mach, P. – PersonEntity: Name: NameFull: Cadoo, K. – PersonEntity: Name: NameFull: Bidzinski, M. – PersonEntity: Name: NameFull: Ariyoshi, K. – PersonEntity: Name: NameFull: Wu, X. – PersonEntity: Name: NameFull: Frentzas, S. – PersonEntity: Name: NameFull: Mattar, A. – PersonEntity: Name: NameFull: Slomovitz, B.M. – PersonEntity: Name: NameFull: Yao, L. – PersonEntity: Name: NameFull: Mckenzie, J. – PersonEntity: Name: NameFull: Meng, R. – PersonEntity: Name: NameFull: Gilbert, L. – PersonEntity: Name: NameFull: Makker, V. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 09 Text: 2025 Supplement 2 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 36 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
